Contact

Payer

Pharma

Provider

Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Immune Globulin (Mar 2017)

Posted by Matt Breese on Mar 10, 2017

Find me on:

According to our recent payer coverage analysis for immune globulin treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A market access breakdown by reimbursement channel shows some differences in immune globulin product coverage. Commercial and health exchange formulary coverage is roughly equivalent, whereas medicare formularies have a slightly greater percentage of covered lives. 


mmit-reality-check-ivig.png

Source: MMIT data as of Q1 2017

Trends:  A recent study, the largest ever conducted for CIPD, provides an example of how manufacturers can optimize relatively limited patient population learnings in a rare disease class. More collaboration for disease areas like this, along with more aggregated data, provides promise for future evolution of treatments.

In the full Reality Check on immune globulin treatments below, MMIT's team of experts takes a deeper look into the clinical characteristics, drug market access and payer coverage to summarize key findings within the class.

To read the full Reality Check on immune globulin treatments with key findings on clinical characteristics, IVIG drug market access and payer coverage, please click on the button below: 

reality-check-thumbnail-v1-1.png

View Reality Check

Topics: Specialty, Market Access, Branding & Marketing